Clinigen Group acquires oncology support product from Novartis

AIM-listed pharmaceutical products and services business Clinigen Group has acquired Cardioxane (dexrazoxane) from Novartis for 33m dollars in cash, payable in two tranches.

AIM-listed pharmaceutical products and services business Clinigen Group has acquired Cardioxane (dexrazoxane) from Novartis for 33m dollars in cash, payable in two tranches.

Under the terms of the agreement, Clinigen will assume responsibility for manufacturing, registration, distribution, and commercialization of the product in countries where current marketing authorizations exist. This includes European, Asian and Latin American territories.

Cardioxane, an oncology support therapy, is a cardioprotective agent used to prevent the cardiotoxicity of anthracycline chemotherapy for patients with advanced and/or metastatic breast cancer.

According to Clinigen, there is an opportunity to revitalize Cardioxane- which it said has no direct licensed competition in the anthracycline therapy cardioprotection space- by utilizing new commercialization, market and indication strategies over the next five years.

The group said that historic revenues for Cardioxane have been approximately $11-12m per annum. Clinigen is targeting a gross margin of 60%.

Latin America seen as strong marketAccording to the group, Latin America is a strong market for Cardioxane, and is of particular interest to Clinigen, because it is a territory in which the group wishes to expand its reach and which may improve access routes for existing portfolio products such as Foscavir, as well as products that Clinigen may acquire in the future.

Peter George, Chief Executive Officer of Clinigen, said: "Acquiring Cardioxane from Novartis is another major step forward for us".

He added: "Cardioxane fits particularly well within our portfolio. We have been looking for medicines that complement Foscavir and Cardioxane does this by extending our role in oncology support. Together with our recent addition of VIBATIV, which further builds on our anti-infective capability, we are delivering on our mission to supply the right drug to the right patient at the right time."

Clinigen Group's share price was up 7.59% to 255p at 14:36 on Tuesday.

MF

Recommended

Ocado faces a “crunch” year – should you buy or avoid?
Share tips

Ocado faces a “crunch” year – should you buy or avoid?

Ocado was one of the big winners from the pandemic as customers moved online. But now it’s struggling, and losses are growing. So, asks Rupert Hargrea…
27 May 2022
What to buy as the tech-stock bull market crashes
Tech stocks

What to buy as the tech-stock bull market crashes

The decade-long bull market in tech stocks has come to a rapid halt. Investors need to distinguish solid stocks from speculative ones rather than just…
27 May 2022
Share tips of the week – 27 May
Share tips

Share tips of the week – 27 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
27 May 2022
Marks & Spencer shares look cheap – should you buy in?
Retail stocks

Marks & Spencer shares look cheap – should you buy in?

Marks & Spencer shares have been a disappointment for investors for two decades. But with the company now on something of a comeback, Rupert Hargreave…
25 May 2022

Most Popular

Scottish Mortgage Investment Trust has fallen hard. But is now the time to buy?
Investment trusts

Scottish Mortgage Investment Trust has fallen hard. But is now the time to buy?

After a spectacular couple of decades, the Scottish Mortgage Investment Trust has fallen by almost 45% so far this year. Rupert Hargreaves asks if no…
26 May 2022
The world’s hottest housing markets are faltering – is the UK next?
House prices

The world’s hottest housing markets are faltering – is the UK next?

As interest rates rise, house prices in the world’s most overpriced markets are starting to fall. The UK’s turn will come, says John Stepek. But will …
23 May 2022
Is it time to pick up growth stock bargains yet?
Investment strategy

Is it time to pick up growth stock bargains yet?

If you’re thinking of picking up some bargains from the tech stock crash, beware – there are still plenty of “growth traps” out there. John Stepek exp…
26 May 2022